At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HRMY Harmony Biosciences Holdings, Inc.
Post-Mkt 01-09 16:08:23 EST
38.55
+0.68
+1.80%
盘后38.55
+0.000.00%
16:04 EST
High38.75Low37.02Vol736.48K
Open37.99D1 Closing37.87Amplitude4.57%
Mkt Cap2.22BTradable Cap1.72BTotal Shares57.60M
T/O28.09MT/O Rate1.65%Tradable Shares44.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Harmony Biosciences Is Maintained at Buy by Truist Securities
Dow Jones  ·  01-09 01:12
Harmony Biosciences Is Maintained at Buy by Truist Securities
Harmony Biosciences price target lowered to $45 from $48 at Truist
TIPRANKS  ·  01-08 20:55
Harmony Biosciences price target lowered to $45 from $48 at Truist
Harmony Biosciences to Present at J.P. Morgan Healthcare Conference
Reuters  ·  01-07 21:05
Harmony Biosciences to Present at J.P. Morgan Healthcare Conference
Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares
Reuters  ·  2025-12-18
Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares
BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences
Reuters  ·  2025-12-16
BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences
Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials
Reuters  ·  2025-12-16
Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials
Beacon Biosignals Announces Partnership With Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative Eeg
THOMSON REUTERS  ·  2025-12-16
Beacon Biosignals Announces Partnership With Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative Eeg
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Reuters  ·  2025-12-10
Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares
Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome
Reuters  ·  2025-12-08
Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome
Harmony Biosciences (HRMY) Is Up 7.6% After GR Pitolisant Bioequivalence Win and Patent Runway Push
Simply Wall St.  ·  2025-12-05
Harmony Biosciences (HRMY) Is Up 7.6% After GR Pitolisant Bioequivalence Win and Patent Runway Push
Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome
Reuters  ·  2025-12-02
Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating
MT Newswires Live  ·  2025-12-01
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating
Harmony Biosciences : Mizuho Raises Target Price to $46 From $39
THOMSON REUTERS  ·  2025-12-01
Harmony Biosciences : Mizuho Raises Target Price to $46 From $39
Harmony Biosciences Holdings (HRMY) Is Up 6.8% After Positive Pitolisant Study Results Are Patent Hopes Justified?
Simply Wall St.  ·  2025-11-28
Harmony Biosciences Holdings (HRMY) Is Up 6.8% After Positive Pitolisant Study Results Are Patent Hopes Justified?
Harmony Biosciences CFO Sandip Kapadia Reports Sale of Common Shares
Reuters  ·  2025-11-26
Harmony Biosciences CFO Sandip Kapadia Reports Sale of Common Shares
Positive Outlook on Harmony Biosciences Holdings: Promising Pipeline Developments and Revenue Growth Potential
TIPRANKS  ·  2025-11-25
Positive Outlook on Harmony Biosciences Holdings: Promising Pipeline Developments and Revenue Growth Potential
BUZZ- Harmony Biosciences jumps as co announces positive results from sleep disorder drug study
Reuters  ·  2025-11-24
BUZZ- Harmony Biosciences jumps as co announces positive results from sleep disorder drug study
Harmony Biosciences Price Target Maintained With a $42.00/Share by Needham
Dow Jones  ·  2025-11-24
Harmony Biosciences Price Target Maintained With a $42.00/Share by Needham
Promising Developments and Upcoming Catalysts Drive Buy Rating for Harmony Biosciences
TIPRANKS  ·  2025-11-24
Promising Developments and Upcoming Catalysts Drive Buy Rating for Harmony Biosciences
Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results
MT Newswires Live  ·  2025-11-24
Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results

Introduction

Company Name.
Harmony Biosciences Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Issue price:
--